1. Pink Sheet
  2. >>Market Access

Pricing And R&D Transparency Proposals Face Pushback At WHA

 
• By Francesca Bruce

A draft resolution on the transparency of medicine prices and R&D costs is being discussed this week by World Health Organization members, but the pharmaceutical industry says some measures will be damaging for medicines access.

Sphere
WHO Member States Are Calling For More Transparency On Pricing And R&D Costs

A draft resolution calling on countries to share information on medicine prices and for companies to disclose clinical trial costs is under discussion at the World Health Assembly this week. Public health advocates and numerous WHO member states say the measures in the resolution would improve access to medicines, but the pharmaceutical industry claims that they would restrict access in poorer countries.

The 72nd World Health Assembly is underway in Geneva this week, and up for heated discussion is a draft resolution...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Government Payers

More from Market Access

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 
• By Francesca Bruce

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.

Alzheimer’s Drug Leqembi May Be On Course To India, Kisunla In The Wings

 
• By Anju Ghangurde

Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.

Pink Sheet Podcast: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

 
• By Derrick Gingery, Francesca Bruce, Cathy Kelly, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.